Maintenance Lynparza Tablets Approved in Ovarian Cancer: Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
According to the article, "...maintenance treatment with Lynparza showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapse, BRCA-mutant ovarian cancer. In Study 19, the risk of progression or death was reduced by 65%...regardless of BRCA status."
By the way, the article also stated that Lynparza tablets and capsules are not interchangeable and that the capsules are being phased out of the US. Apparently, it will only be available through the Lynparza Specialty Pharmacy Network.